NICE is unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer because Novartis did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)